CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Sign Up to like & getrecommendations! Published in 2023 at "FEBS open bio"
DOI: 10.1002/2211-5463.13625
Abstract: Cutaneous T-cell lymphoma (CTCL) encompasses two main subtypes: mycosis fungoides and Sezary syndrome. Global response rates for the systemic treatment of mycosis fungoides and Sezary syndrome are approximately 30% and none of these treatments are… read more here.
Keywords: ctcl; ccr4 il2; mouse; model ... See more keywords